CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Erlotinib Hydrochloride +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02535338
NCT02535338Phase 2Completed
CompareCT.gov

A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer

National Cancer Institute (NCI)·interventional·Posted Aug 28, 2015·Updated Mar 3, 2025

In Brief

A Phase 2 clinical trial evaluating Erlotinib Hydrochloride, Laboratory Biomarker Analysis, and 2 other interventions for Recurrent Lung Non-Small Cell Carcinoma and Stage IV Lung Non-Small Cell Cancer AJCC v7. Completed, enrolled 11 participants across 6 sites.

Detailed Summary

This phase I/II trial studies the side effects and best dose of onalespib lactate when given together with erlotinib hydrochloride and to see how well they work in treating patients with EGFR-mutant non-small cell lung cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Erlotinib hydrochloride and onalespib lactate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 28, 2015
Enrollment StartApr 11, 2016
Primary CompletionSep 3, 2021
Study CompletionSep 8, 2021
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 10.8 years ago

Interventions

Erlotinib Hydrochloridedrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies

Onalespib Lactatedrug

Given IV

Pharmacological Studyother

Correlative studies